Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 813-399-9 | CAS number: 1821694-26-1
Direct observations: clinical cases, poisoning incidents and other
Administrative data
- Endpoint:
- direct observations: clinical cases, poisoning incidents and other
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Acceptable well-documented publication.
Data source
Reference
- Reference Type:
- publication
- Title:
- Magnesium and the anaesthetist
- Author:
- Gambling, D.R., Birmingham, C.L., Jenkins, L.C.
- Year:
- 1 988
- Bibliographic source:
- Can J. Anaesth; 1988/ 35: 6 / p.p. 644-54
Materials and methods
- Study type:
- other: treatment of patients in case of hypomagnesemia
- Endpoint addressed:
- acute toxicity: oral
Test guideline
- Qualifier:
- no guideline required
- Principles of method if other than guideline:
- Oral doses are reported for patients with continuoses magnesium losses.
- GLP compliance:
- no
Test material
- Reference substance name:
- Magnesium glucoheptonate
- IUPAC Name:
- Magnesium glucoheptonate
- Reference substance name:
- Bis(D-glycero-D-ido-heptonato)magnesium
- EC Number:
- 270-642-6
- EC Name:
- Bis(D-glycero-D-ido-heptonato)magnesium
- Cas Number:
- 68475-44-5
- IUPAC Name:
- 68475-44-5
- Details on test material:
- - Name of test material (as cited in study report): Magnesium glucoheptonate
Constituent 1
Constituent 2
Method
- Type of population:
- other: patients
- Route of exposure:
- oral
- Reason of exposure:
- other: therapy of hypomagnesemia
- Exposure assessment:
- measured
Results and discussion
Any other information on results incl. tables
Oral replacement, using magnesium glucoheptonate 20-50 mmol/day in divided doses, is used when magnesium losses are continuous.
Applicant's summary and conclusion
- Conclusions:
- Oral replacement, using magnesium glucoheptonate 20-50 mmol/day in divided doses, is used when magnesium losses are continuous.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
